Evidence map›Paper›PMID 32798219›Full record

ArticleThe Journal of cell biology2020

CDC42EP5/BORG3 modulates SEPT9 to promote actomyosin function, migration, and invasion.

Aaron J Farrugia, Javier Rodríguez, Jose L Orgaz, María Lucas, Victoria Sanz-Moreno, Fernando Calvo

Open access · hybridAbstract read
In one paragraph

Article in The Journal of cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Amoeboid cancer cells at a glance.Journal of cell science · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. SEPT3 as a Potential Molecular Target of Triple-Negative Breast Cancer.International journal of general medicine · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Aaron J FarrugiaDivision of Cancer Biology, The Institute of Cancer Research, London, UK.
Javier RodríguezInstituto de Biomedicina y Biotecnología de Cantabria (Consejo Superior de Investigaciones Científicas, Universidad de Cantabria), Santander, Spain.
Jose L OrgazCentre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, UK.
María LucasInstituto de Biomedicina y Biotecnología de Cantabria (Consejo Superior de Investigaciones Científicas, Universidad de Cantabria), Santander, Spain.
Victoria Sanz-MorenoCentre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, UK.
Fernando CalvoDivision of Cancer Biology, The Institute of Cancer Research, London, UK.
Universidad de Cantabria · ESQueen Mary University of London · GBInstitute of Cancer Research · GB

Funding

Cancer Research UK 24478Cancer Research UK C33043/A12065Cancer Research UK C33043/A24478Cancer Research UK C57744/A22057
6 · The paper itself

Abstract

Fast amoeboid migration is critical for developmental processes and can be hijacked by cancer cells to enhance metastatic dissemination. This migratory behavior is tightly controlled by high levels of actomyosin contractility, but how it is coupled to other cytoskeletal components is poorly understood. Septins are increasingly recognized as novel cytoskeletal components, but details on their regulation and contribution to migration are lacking. Here, we show that the septin regulator Cdc42EP5 is consistently required for amoeboid melanoma cells to invade and migrate into collagen-rich matrices and locally invade and disseminate in vivo. Cdc42EP5 associates with actin structures, leading to increased actomyosin contractility and amoeboid migration. Cdc42EP5 affects these functions through SEPT9-dependent F-actin cross-linking, which enables the generation of F-actin bundles required for the sustained stabilization of highly contractile actomyosin structures. This study provides evidence that Cdc42EP5 is a regulator of cancer cell motility that coordinates actin and septin networks and describes a unique role for SEPT9 in melanoma invasion and metastasis.

Indexed as

ActinsActomyosinAnimalsCell Line, TumorCell MovementCutaneous Malignant MelanomaCytoskeletonFocal AdhesionsGTP-Binding Protein RegulatorsHumansMelanomaMiceSeptinsSkin NeoplasmsActinsActomyosinCdc42ep5 protein, mouseGTP-Binding Protein Regulatorsseptin 9, mouseSeptins

Identifiers

PMID32798219
PMCPMC7480113
OpenAlexW3049744423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.